RSV InfectionNCT07264478
Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
An observational study of RSV Infection and Disease Burden, run by Beijing Children's Hospital at 1 site in China.
Trial summary
To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- RSV Infection, Disease Burden
- What is being tested?
- uninvolved
- How many people
- 1,100 participants
- Where
- 1 siteChina
- Study dates
- 15 Oct 2022to 30 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. A total of 11 hospitals were selected, each with 100 children, a total of 1100 cases
Who may be able to join
- Hospitalized patients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia
Who cannot join
- Inpatients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia are excluded from any of the following criteria:
- Pneumonia occurring 48 hours after hospitalization;
- Combined with bronchial foreign body;
- Participants in clinical trials of drugs or medical devices;
- Not complete personal and family history and other relevant information.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Diseases, National Center for Children's Health, Beijing, China
To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.
- Conditions
- RSV Infection, Disease Burden
- Being tested
- uninvolved
- Medical subject headings
- Respiratory Syncytial Virus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
uninvolvedOther
uninvolved
What is being measured
The primary outcome is the main question the study is designed to answer.
hospitalization costs
hospitalization costs,pharmcost,testcost,testcost
Measured: duration of hospital stay
Secondary outcomes (1)
hospital day
duration of hospital stay
Measured: duration of hospital stay
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2025
- Study start15 Oct 2022
- Primary completion12 Dec 2025 (estimated)
- Study completion30 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RSV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Baoping XU, Beijing Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07264478
- Sponsor's protocol ID
- BCH lung 22
- Status last verified
- Dec 2025
- First submitted
- 12 Oct 2023
- Last updated
- 4 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Diseases, National Center for Children's Health, Beijing, China
- ClinicalTrials.gov ID
- NCT07264478
- Acronym / sponsor ID
- BCH lung 22
- Conditions
- RSV Infection, Disease Burden
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,100 participants (estimated)
- Lead sponsor
- Beijing Children's HospitalUniversity, hospital or other
- Study start
- 15 Oct 2022 (actual)
- Primary completion
- 12 Dec 2025 (estimated)
- Study completion
- 30 Dec 2025 (estimated)
- First posted
- 4 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. A total of 11 hospitals were selected, each with 100 children, a total of 1100 cases
Key inclusion criteria (1 listed)
- Hospitalized patients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia
Key exclusion criteria (5 listed)
- Inpatients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia are excluded from any of the following criteria:
- Pneumonia occurring 48 hours after hospitalization;
- Combined with bronchial foreign body;
- Participants in clinical trials of drugs or medical devices;
- Not complete personal and family history and other relevant information.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| uninvolveduninvolved | Other | – |
Primary outcome
hospitalization costs
Time frame: duration of hospital stay
hospitalization costs,pharmcost,testcost,testcost
1 secondary outcome
hospital day
Time frame: duration of hospital stay
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for RSV Infection
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
Not yet recruitingPhase 3
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection
RecruitingObservational study
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
COVID-19, SARS-CoV-2 Infection, RSV
RecruitingPhase 2/3
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
RSV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of RSV Infection and Disease Burden, run by Beijing Children's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hospitalization costs (time frame: duration of hospital stay). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.